Company release
Nanoform Finland Plc
March 25, 2022
04.45 p.m. Finnish time / 03.45 p.m. Swedish time
Nanoform Finland Plc – Manager’s transactions – Gonçalo Andrade
Manager’s transaction related to Nanoform Finland Plc’s other senior manager Gonçalo Andrade’s purchase of shares.
____________________________________________
Person subject to the notification requirement
Name: Gonçalo Andrade
Position: Other senior manager
Issuer: Nanoform Finland Plc
LEI: 743700JJO2NU8LBS1592
Notification type: INITIAL NOTIFICATION
Reference number: 743700JJO2NU8LBS1592_20220325143131_4
____________________________________________
Transaction date: 2022-03-25
Venue not applicable
Instrument type: SHARE
ISIN: FI4000330972
Nature of the transaction: PURCHASE
Transaction details:
Volume: 2,000
Unit price: 4.45 EUR
For further information, please contact:
Peter Hänninen, General Counsel
peter.hanninen@nanoform.com / +358 50 353 0408
For investor relations queries, please contact:
Henri von Haartman, Director of Investor Relations
hvh@nanoform.com / +46 7686 650 11
About Nanoform
Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to provide hope for patients in developing new and improved medicines utilizing Nanoform’s platform technologies. The company focuses on reducing clinical attrition and on enhancing drug molecules’ performance through its nanoforming technologies and formulation services. Nanoform’s capabilities include GMP manufacturing, and its services span the small to large molecule development space with a focus on solving key issues in drug solubility and bioavailability and on enabling novel drug delivery applications. Nanoform’s shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: Danske Bank A/S, Finland Branch, +358 40 744 1900. For more information please visit http://www.nanoform.com